Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
Why Is Rubius Therapeutics (RUBY) Stock Up 35% Today?
Why Is Rubius Therapeutics (RUBY) Stock Down 16% Today?
Hot Penny Stocks to Buy This Week? 3 to Watch Now
Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
3 High Volume Penny Stocks To Watch Before Next Week
Rubius Therapeutics, Inc. (RUBY) Upgraded to Buy: What Does It Mean for the Stock?
Rubius: Poor Data, Punishing Environment, Beaten Stock
Rubius Therapeutics to Present at the Jefferies Global Healthcare Conference
Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting
Rubius Therapeutics to Announce First Quarter 2022 Financial Results
Here Are 3 Penny Stocks You Need to Know About in May 2022
Rubius Shares Plunge After Early Data From RTX-240 Solid Tumor Trial
Rubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Solid Tumors on April 8, 2022, at 1:15 PM ET
RUBY PIPELINE FILES TO REORGANIZE UNDER CHAPTER 11 OF THE BANKRUPTCY CODE
Rubius Looks Attractive Before AACR Data Readout
Rubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual Meeting
Rubius Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results
Rubius Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
Is a Surprise Coming for Rubius Therapeutics (RUBY) This Earnings Season?
Rubius Therapeutics to Announce Third Quarter 2021 Financial Results
Rubius Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference and H.C. Wainwright 23rd Annual Global Investment Conference in September 2021
Rubius Therapeutics Appoints Jim Jogerst as Chief Business Officer
Should You Buy Rubius Therapeutics (RUBY) Ahead of Earnings?
5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates
Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy
Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors
Rubius: Early Positive Data, But Stretched Valuation
Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting
Rubius Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting
FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings
3 Biotech Stocks to Avoid Right Now
Implied Volatility Surging for Rubius Therapeutics (RUBY) Stock Options
Rubius Therapeutics Prices Upsized Public Offering of Common Stock
Rubius Therapeutics Announces Proposed Public Offering of Common Stock
Rubius Therapeutics Stock Trading Higher On Positive Efficacy, Safety RTX-240 Data In Solid Tumor Study
Why Rubius Therapeutics Stock Is Skyrocketing Today
RUBY Stock Alert: The Promising Cancer Drug News That Has Rubius Therapeutics Rocketing Today
Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity
RUBY Stock Price Increases Over 40% Pre-Market: Why It Happened
RUBY Stock Price Increased 49.12% After Hours: Why It Happened
Rubius Therapeutics Announces Webcast to Review Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors
Rubius Therapeutics to Present Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target
Rubius Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
Rubius Therapeutics to Participate in Guggenheim Healthcare Talks | 2021 Oncology Days
Rubius: Watson, We Have No Data
Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
Rubius Therapeutics to Participate in Evercore ISI 3rd Annual HealthCONx Conference